<?xml version='1.0' encoding='utf-8'?>
<document id="25789148"><sentence text="Commentary on prevention a possible drug-drug interaction: is concurrent administration of orlistat and pioglitazone increase the risk of durg-induced hepatotoxicity?"><entity charOffset="104-116" id="DDI-PubMed.25789148.s1.e0" text="pioglitazone" /></sentence><sentence text="Drug-drug interactions (DDIs) are an emerging threat to public health and are difficult to detect" /><sentence text=" To prevent DDIs and their burden, the possible DDIs should be kept in mind" /><sentence text=" We know that the obesity predisposes to the development of insulin resistance and type 2 diabetes" /><sentence text=" Therefore, combinational uses of antiobesity drugs and glucose-lowering drugs are very common"><entity charOffset="56-63" id="DDI-PubMed.25789148.s5.e0" text="glucose" /></sentence><sentence text=" As the hepatotoxicity of both pioglitazone (an antidiabetic drug) and orlistat (an antiobesity drug) has been shown in some cases, the aim of this study was to evaluate the interaction of pioglitazone and orlistat in human hepatocellular cell line human hepatocellular carcinoma (HepG2) cells to determine their effect on liver toxicity"><entity charOffset="31-43" id="DDI-PubMed.25789148.s6.e0" text="pioglitazone" /><entity charOffset="189-201" id="DDI-PubMed.25789148.s6.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.25789148.s6.e0" e2="DDI-PubMed.25789148.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25789148.s6.e0" e2="DDI-PubMed.25789148.s6.e1" /></sentence><sentence text="" /><sentence text="Human hepatocellular carcinoma cells were treated with 25 μM Pioglitazon (Pio), 20 μM Orlistat (Orl) pioglitazone, orlistat or combination of them"><entity charOffset="101-113" id="DDI-PubMed.25789148.s8.e0" text="pioglitazone" /></sentence><sentence text=" The MTT assay was used to assess cell viability"><entity charOffset="5-8" id="DDI-PubMed.25789148.s9.e0" text="MTT" /></sentence><sentence text="" /><sentence text="Pioglitazone and orlistat combination caused a loss of HepG2 cell viability"><entity charOffset="0-12" id="DDI-PubMed.25789148.s11.e0" text="Pioglitazone" /></sentence><sentence text=" While pioglitazone (25 μM) and orliatat (20 μM) alone decreased the cell viability around 91% and 85% respectively (notsignificant, P &gt; 0"><entity charOffset="7-19" id="DDI-PubMed.25789148.s12.e0" text="pioglitazone" /></sentence><sentence text="05), the combination of these two drugs reduced the amount of viable cells to 55% which was significant when compared with each drug alone (P &lt; 0" /><sentence text="001)" /><sentence text="" /><sentence text="Revealing the significant loss of viability of HepG2 cells in the combination use of pioglitazone and orlistat indicates these two drugs should not be administered at the same time to prevent their hepatotoxic effects especially in patients with liver dysfunction"><entity charOffset="85-97" id="DDI-PubMed.25789148.s16.e0" text="pioglitazone" /></sentence><sentence text="" /></document>